Protara Therapeutics, Inc. (TARA) News

Protara Therapeutics, Inc. (TARA): $3.25

0.12 (+3.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TARA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 437

in industry

Filter TARA News Items

TARA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

TARA News Highlights

  • For TARA, its 30 day story count is now at 2.
  • Over the past 22 days, the trend for TARA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about TARA are RARE.

Latest TARA News From Around the Web

Below are the latest news stories about Protara Therapeutics Inc that investors may wish to consider to help them evaluate TARA as an investment opportunity.

Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference

NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on February 9, 2022 at 4:00 PM ET. A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https:/

Yahoo | February 1, 2022

Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Jathin Bandari, M.D., as Chief Medical Officer. Dr. Bandari is a practicing urologic oncologist, recently serving at the University of Rochester where he specialized in both minimally invasive urologic oncology and advanced open pelvic retroperitoneal cancer surgery, an

Yahoo | January 10, 2022

Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright BioConnect Virtual Conference being held from January 10-13, 2022. The prerecorded presentation will become available on Monday, January 10, 2022 at 7:00am ET and can be accessed by visiting the Events and Pr

Yahoo | January 4, 2022

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | December 8, 2021

Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview

– TARA-002 Confirmatory Large-Scale GMP Comparability Complete – – U.S. FDA Cleared the Company’s IND Application for TARA-002 in NMIBC; Company Plans to Initiate Phase 1 Clinical Trial by Year-End – – Strong Cash, Cash Equivalents, and Marketable Debt Securities of $138.4M as of September 30, 2021 – NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, tod

Yahoo | November 4, 2021

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 44,000 shares of common stock to Mary Grendell, Protara’s new General Counsel. Each stock option has an exercise price per share equal to $6.81 per share, Protara’s closing trading price on October 25, 2021,

Yahoo | October 25, 2021

11 Things to Know About Protara Therapeutics as TARA Stock Soars on Big FDA News

Protara Therapeutics (TARA) stock is heading higher on Tuesday following some major news from the FDA concerning clinical trials.

William White on InvestorPlace | October 12, 2021

FREY Stock: 2 Reasons Why Freyr Battery Investors Are Feeling Fired Up Today

Freyr Battery (FREY) stock is on the move Tuesday and there's a couple of recent pieces of news behind its rise investors will want to know.

William White on InvestorPlace | October 12, 2021

Hot Penny Stocks for Tuesday: Today’s 10 Biggest Movers

Penny stocks are on the move Tuesday and we're taking a look at what's hot among traders of the volatile investments today.

William White on InvestorPlace | October 12, 2021

Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer

- Company Plans to Initiate Phase 1 Study of TARA-002 by Year-End - - IND Application Included Submission of Confirmatory Large-Scale GMP Comparability Data - NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for TARA-002, an

Yahoo | October 12, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5377 seconds.